Detection of High-Risk Human Papillomaviruses in the Prevention of Cervical Cancer in India

  • Baskaran, Krishnan (Department of Biochemistry, Rajah Muthiah Medical College & Hospital, Annamalai University) ;
  • Kumar, P Kranthi (Department of Genetics, Narayana Medical College & Hospital) ;
  • Karunanithi, Santha (Department of Biochemistry, Rajah Muthiah Medical College & Hospital, Annamalai University) ;
  • Sethupathy, Subramanian (Department of Biochemistry, Rajah Muthiah Medical College & Hospital, Annamalai University) ;
  • Thamaraiselvi, B (Department of Gynecology and Obstetrics, Thanjavur Medical College) ;
  • Swaruparani, S (Department of Gynecology and Obstetrics, Thanjavur Medical College)
  • Published : 2016.01.11


Human papillomaviruses (HPVs) are small, non-enveloped, double-stranded DNA viruses that infect epithelial tissues. Specific genotypes of human papillomavirus are the single most common etiological agents of cervical intraepithelial lesions and cervical cancer. Cervical cancer usually arises at squamous metaplastic epithelium of transformation zone (TZ) of the cervix featuring infection with one or more oncogenic or high-risk HPV (HR-HPV) types. A hospital-based study in a rural set up was carried out to understand the association of HR-HPV with squamous intraepithelial lesions (SILs) and cervical cancer. In the present study, HR-HPV was detected in 65.7% of low-grade squamous intraepithelial lesions (LSILs), 84.6% of high-grade squamous intraepithelial lesions (HSILs) and 94% of cervical cancer as compared to 10.7% of controls. The association of HPV infection with SIL and cervical cancer was analyzed with Chi square test (p<0.001). The significant association found confirmed that detection of HR-HPV is a suitable candidate for early identification of cervical precancerous lesions and in the prevention of cervical cancer in India.


Human papillomavirus (HPV);high-risk HPV;HPV testing;cervical cancer


  1. Agorastos T, Chatzistamatiou K, Katsamagkas T, et al (2015). Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PLoS one, 10, 119755.
  2. Bhatla N, Lal N, BaoYP, Ng T, Qiao YL (2008). A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine, 26, 2811-7.
  3. Bosch FX, Burchell AN, Schiffman M, et al (2008). Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine, 26, 1-16.
  4. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65.
  5. Bosch FX, Qiao YL, Caslellsague X (2006). Chapter 2: The epidemiology of human papillomavirus infection and its association with cervical cancer. Int J Gynecol Obstet, 94, 8-21.
  6. Burd EM (2003). Human papillomavirus and cervical cancer. Clin Microbiol Rew, 16, 1-17.
  7. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL (2006). Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine, 24, 26-34.
  8. Dijkstra MG, Snijders PJF, Arbyn M, et al (2014). Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol, 25, 927-35.
  9. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004). Classification of papillomaviruses. Virology, 324, 17-27.
  10. Duarte-Franco E, Franco EL (2004). Cancer of the uterine cervix. BMC Womens Health, 4, 13.
  11. Fey MC and Beal MW (2004). Role of human papillomavirus testing in cervical cancer prevention. J Midwifery Womens Health, 49, 4-13.
  12. GLOBOCAN 2012. Available at:
  13. Guo M, Sneige N, Silva EG, et al (2007). Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol, 20, 256-66.
  14. Heymans J, Benoy IH, Poppe W, Depuydt CE (2011). Typespecific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer, 129, 903-9.
  15. Hoppenot C, Stampler K, Dunton C (2012). Cervical cancer screening in high- and low-resource countries: implications and new developments. Obstet Gynecol Surv, 67, 658-67.
  16. Lu KH and Burke TW (2000). Early cervical cancer. Curr Treat Options Oncol, 1, 147-55.
  17. Mayrand MH, Duarte-Franco E, Rodrigues I, et al (2007). Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med, 357, 1579-88.
  18. McAdam M, Sakita J, Tarivonda L, Pang J, Frazer IH (2010). Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting. PLoS, 5, 13266.
  19. Moscicki AB, Schiffman M, Kjaer S, Villa LL (2006). Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine, 24, 42-51.
  20. Munoz N, Bosch FX, de Sanjose S, et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27.
  21. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine, 24, 1-10.
  22. Rijkaart DC, Berkhof J, van Kemenade FJ, et al (2012). HPV DNA testing in population-based cervical screening (VUSAScreen study): results and implications. Br J Cancer, 106, 975-81.
  23. Ronco G and Rossi PG (2008). New paradigms in cervical cancer prevention: opportunities and risks. BMC Womens Health, 8, 1-4.
  24. Ronco G, Dillner J, Elfstrom KM, et al (2014). Efficacy of HPVbased screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, 383, 524-32.
  25. Sankaranarayanan R, Nene BM, Shastri SS, et al (2009). HPV screening for cervical cancer in rural India. N Engl J Med, 360, 1385-94.
  26. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007). Human papillomavirus and cervical cancer. Lancet, 370, 890-907.
  27. Schiffman M, Wentzensen N, Wacholder S, et al (2011). Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst, 103, 368-83.
  28. Schiffman MH, Bauer HM, Hoover RN, et al (1993). Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst, 85, 958-64.
  29. Smith SJ, Lindsay L, Hoots B, et al (2007). Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer, 121, 621-32.
  30. Solomon D, Davey D, Kurman R, et al (2002). The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA, 287, 2114-9.
  31. Szostek S, Klimek M, Zawilinska B, Kosz-Vnenchak M (2008). Genotype-specific human papillomavirus detection in cervical smears. Acta Biochim Pol, 55, 687-92.
  32. Tjalma WA, Van Waes TR, Van den Eeden LE, Bogers JJ (2005). Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix. Best Pract Res Clin Obstet Gynecol, 19, 469-83.
  33. Villa LL (2006). Chapter 1: Biology of genital human papillomaviruses. Int J Gynecol Obstet, 94, S3-7.
  34. Wright TC Jr (2007). Cervical cancer screening in the 21st century: is it time to retire the Pap smear? Clin Obstet Gynecol, 50, 313-23.